GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DexTech Medical AB (XSAT:DEX) » Definitions » Debt-to-EBITDA

DexTech Medical AB (XSAT:DEX) Debt-to-EBITDA : 0.00 (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is DexTech Medical AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

DexTech Medical AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr0.00 Mil. DexTech Medical AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr0.00 Mil. DexTech Medical AB's annualized EBITDA for the quarter that ended in Sep. 2024 was kr-5.17 Mil. DexTech Medical AB's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for DexTech Medical AB's Debt-to-EBITDA or its related term are showing as below:

XSAT:DEX's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.41
* Ranked among companies with meaningful Debt-to-EBITDA only.

DexTech Medical AB Debt-to-EBITDA Historical Data

The historical data trend for DexTech Medical AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexTech Medical AB Debt-to-EBITDA Chart

DexTech Medical AB Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

DexTech Medical AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of DexTech Medical AB's Debt-to-EBITDA

For the Biotechnology subindustry, DexTech Medical AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexTech Medical AB's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DexTech Medical AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where DexTech Medical AB's Debt-to-EBITDA falls into.



DexTech Medical AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

DexTech Medical AB's Debt-to-EBITDA for the fiscal year that ended in Jun. 2024 is calculated as

DexTech Medical AB's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -5.172
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


DexTech Medical AB  (XSAT:DEX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


DexTech Medical AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of DexTech Medical AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


DexTech Medical AB Business Description

Traded in Other Exchanges
N/A
Address
Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB develops candidate medications with applications within urological oncology, for prostate cancer. Its medication candidates include GuaDex, OsteoDex, and SomaDex, among others. The company conducts operations in medical research with the development of new drug candidates mainly in urological oncology, but also other cancer diseases and for non-malignant diseases. The company has a well built clinical base with valuable specialist expertise from research laboratories and manufacturing to clinical oncology.